Search

BioCryst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

9.75 -1.81

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

9.59

Massimo

9.94

Metriche Chiave

By Trading Economics

Entrata

-1.1B

-722M

Vendite

-250M

156M

P/E

Media del settore

7.603

60.149

EPS

0.14

Margine di Profitto

-461.478

Dipendenti

435

EBITDA

-966M

-700M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+129.57% upside

Dividendi

By Acuity

Utili prossimi

3 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

318M

2.7B

Apertura precedente

11.56

Chiusura precedente

9.75

Notizie sul Sentiment di mercato

By Acuity

50%

50%

172 / 342 Classifica in Healthcare

BioCryst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 lug 2026, 23:46 UTC

News

PayPal Holdings Inc. shares are lower in after-market trading despite expanding buy now, pay later options in the UK with a new Pay in 30 Days feature.

14 lug 2026, 23:41 UTC

Event
News

Biogen Inc shares are higher in after-market trading following positive Phase 2 CELIA study results for diranersen, which targets tau in early Alzheimer's disease.

14 lug 2026, 23:32 UTC

Social Media
News

Advanced Micro Devices shares rose in after-market hours following price target increases by analysts, including KeyBanc's $725 target amid strong demand for EPYC processors.

14 lug 2026, 23:32 UTC

News
Social Media

Micron Technology's stock rose in after-market trading following a lower-than-expected inflation report and positive sentiment from IBM regarding memory chip demand.

14 lug 2026, 23:31 UTC

News
Social Media

Amazon.com Inc shares are higher in after-market trading amid positive sentiment. Analysts maintain a bullish outlook on the company's long-term investment strategy.

14 lug 2026, 23:31 UTC

News

Netflix shares are higher in after-hours trading, buoyed by investor confidence despite rising subscription costs and regulatory scrutiny amid broader positive market sentiment.

14 lug 2026, 23:31 UTC

News
Social Media

Alphabet Inc signed a fixed-price power purchase agreement for its largest solar-plus-storage project in the U.S. Shares are lower in after-market hours.

14 lug 2026, 23:31 UTC

News
Correlated Moves

Apple Inc. shares were little changed after KeyBanc downgraded the rating to Sell with a price target of $250. OpenAI countered Apple's trade secret lawsuit claims.

14 lug 2026, 23:11 UTC

News

The Australian Dollar is trading higher against the Singapore Dollar, supported by rising crude oil prices and improved U.S. inflation data.

14 lug 2026, 23:06 UTC

News

Fiserv Inc. will release its second-quarter earnings on August 6, 2026, with shares trading higher in after-market hours amid positive sentiment.

14 lug 2026, 23:06 UTC

News

Workday Inc. shares declined slightly in after-market trading following a challenging year, despite reporting 14.7% year-over-year growth in subscription revenue.

14 lug 2026, 23:06 UTC

Macro News
News
Correlated Moves
ETF Constituents

Health Care Select Sector SPDR Fund is trading higher after proposed Medicare reforms by CMS and Anthem's new Alzheimer's testing coverage announcement.

14 lug 2026, 23:06 UTC

News

United States Oil Fund LP trades higher in after-market hours as Iran withdraws from its agreement with the U.S., raising oil supply stability concerns.

14 lug 2026, 23:01 UTC

News

Cintas Corp is higher in after-market trading, with its market capitalization surpassing Target Corp, positioning it 193rd in the S&P 500.

14 lug 2026, 22:32 UTC

Correlated Moves
News

Geopolitical tensions and rising crude oil prices have contributed to an increase in CHF/HKD since Monday's close, reflecting broader market sentiment.

14 lug 2026, 20:52 UTC

Correlated Moves
News

Vanguard Total Bond Market ETF advances in after-hours trading following a significant drop in the U.S. Consumer Price Index, easing inflation concerns and boosting Treasury demand.

14 lug 2026, 20:07 UTC

News
Social Media

eBay shares are lower amid mixed analyst ratings and social media concerns about growth metrics. Jefferies raised the price target to $75 while maintaining an Underperform rating.

14 lug 2026, 20:07 UTC

News

Xcel Energy shares are lower amid a settlement proposal for a $123 million revenue increase, with regulatory hearings scheduled for July 2026.

14 lug 2026, 20:07 UTC

Social Media
Correlated Moves
News
Macro Event

Gold prices rose sharply today, with August futures reaching $4,092 an ounce after cooler CPI data. SPDR Gold Shares also benefited from this upward trend.

14 lug 2026, 20:07 UTC

News
Social Media

Electronic Arts is set to launch EA Sports Madden NFL 27 Arcade Edition on August 6, contributing to positive investor sentiment as shares trade higher.

14 lug 2026, 20:02 UTC

News
Macro Event

American Airlines shares are lower amid mixed options sentiment and elevated trading volume. The stock is set to report earnings on July 23.

14 lug 2026, 20:02 UTC

Correlated Moves
News

Intuitive Surgical shares are lower as Baird cuts price target to $525 from $610. The stock has reached a 25-month low at $395.02.

14 lug 2026, 20:02 UTC

News
Macro Event

Take-Two Interactive shares are trading lower amid recent inflation data, despite earlier gains during the session reflecting broader market pressures in the gaming sector.

14 lug 2026, 19:56 UTC

News

Citigroup maintained its Buy rating on Monster Beverage and raised the price target to $113, contributing to a higher stock price since Monday's close.

14 lug 2026, 19:52 UTC

Correlated Moves
ETF Constituents
News

Fitch affirmed Canada's credit rating at AA+, boosting sentiment for Canadian assets. The iShares MSCI Canada ETF is trading higher, supported by favorable USD/CAD movement.

14 lug 2026, 19:52 UTC

Macro Event
News

NTAL launched to amplify daily participation in NTAP amid strong activity.

14 lug 2026, 19:46 UTC

News

Marriott International shares rise amid positive sentiment from a new collaboration between The Ritz-Carlton and MERIT Beauty, with Macquarie raising its price target to $365.

14 lug 2026, 19:45 UTC

News
Correlated Moves

Intuit Inc. shares are lower amid a class action lawsuit alleging securities fraud and an investigation into potential violations of federal securities laws.

14 lug 2026, 19:41 UTC

Correlated Moves
Macro Event
News

U.S. CPI showed a month-over-month decrease, boosting demand for Treasury bonds. The iShares 20+ Year Treasury Bond ETF remains higher than Monday's close.

14 lug 2026, 19:37 UTC

News
Social Media

KeyBanc maintains Overweight rating on Intel, raising price target to $155. Strong demand for AI-driven CPUs and improved yields support upward movement in shares today.

Confronto tra pari

Modifica del prezzo

BioCryst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

129.57% in crescita

Previsioni per 12 mesi

Media 22.75 USD  129.57%

Alto 32 USD

Basso 12 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per BioCryst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

8

Acquista

1

Mantieni

0

Vendi

Sentiment

By Acuity

172 / 342 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
help-icon Live chat